“Any large scale clinical trial of an Alzheimer’s drug that fails is a massive disappointment to patients,” said Professor Jonathan Schott (UCL Queen Square Institute of Neurology) after the drug gantenerumab failed to show any benefit in cognitive skills.
Read: Guardian
Close
